SYBX - マイア―ルエヌエイ・セラピュ―ティクス （Synlogic Inc.） マイア―ルエヌエイ・セラピュ―ティクスSYBXのチャート
SYBXの企業情報
| symbol | SYBx |
|---|---|
| 会社名 | Synlogic Inc （マイア―ルエヌエイ・セラピュ―ティクス） |
| 分野（sector） | ― |
| 産業（industry） | ― |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Synlogic Inc. formerly Mirna Therapeutics Inc. is engaged in the development of a novel class of living treatments Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions including inflammatory bowel disease cancer and metabolic conditions such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU. マイア―ルエヌエイ・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、鎖長の短いマイクロRNAベ―スを用い抗がん剤の開発に従事する。遺伝子の発現パタ―ンの違いでがんが発生し、腫瘍を抑制するマイクロRNAはがんにより減少することを利用。通常の細胞ががん細胞に変わるのを防ぐ腫瘍抑制マイクロRNAを特定する。本社はテキサス州オ―スティン。 Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic therapeutics that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology. |
| 本社所在地 | 301 Binney St. Suite 402 Cambridge MA 02142 USA |
| 代表者氏名 | Michael F. Powell マイケル・F・パウエル |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-401-9975 |
| 設立年月日 | 39417 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 63人 |
| url | www.synlogictx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sybx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -47.49700 |
| 終値（lastsale） | 12.3 |
| 時価総額（marketcap） | 312800660.4 |
| 時価総額 | 時価総額（百万ドル） 229.89580 |
| 売上高 | 売上高（百万ドル） 0.83000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 87.36980 |
| 当期純利益 | 当期純利益（百万ドル） -49.37700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Synlogic Inc revenues decreased 73% to $608K. Net loss increased 54% to $25.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 41% to $19.2M (expense) General and administrative increase of 55% to $8.4M (expense) Interest expense increase of 73% to $26K (expense). |
SYBXのテクニカル分析
SYBXのニュース
Nordstrom, Bed Bath & Beyond, Synlogic among premarket losers'' pack 2023/01/20 13:17:23 Seeking Alpha
Tempo Automation (TMPO) -15%.NeuroSense Therapeutics (NRSN) -15%.Synlogic (SYBX) -15%.Panbela Therapeutics (PBLA) -16%.Celyad Oncology (CYAD) -11%.Apexigen (APGN) -10%.TC Biopharm…
Synlogic (SYBX) Investor Presentation - Slideshow (NASDAQ:SYBX) 2023/01/19 22:35:19 Seeking Alpha
The following slide deck was published by Synlogic, Inc.
Little Known Factors That Could Affect shares: Avaya Holdings Corp. (NYSE:AVYA -2.61%), Synlogic, Inc. (NASDAQ:SYBX 0.85%) 2023/01/19 15:57:37 Stock Equity
AVYA has seen its SMA50 which is now -66.82%. In looking the SMA 200 we see that the stock has seen a -91.29%. SYBX has seen its SMA50 which is … The post Little Known Factors That Could Affect shares: Avaya Holdings Corp. (NYSE:AVYA -2.61%), Synlogic, Inc. (NASDAQ:SYBX 0.85%) appeared first on Stocks Equity .
Synlogic rises ~10% as metabolic disorder drug gets FDA rare pediatric disease status 2023/01/19 12:25:22 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) granted rare pediatric disease designation ((RPDD)) to Synlogic''s (SYBX) SYNB1934 to potentially treat phenylketonuria ((PKU)).PKU is a…
Synlogic Inc. (NASDAQ:SYBX) Drops -12.93% In One Week: What’s Boosting Its Stock? 2022/11/24 16:00:00 Marketing Sentinel
In last trading session, Synlogic Inc. (NASDAQ:SYBX) saw 0.14 million shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $0.62 trading at -$0.02 or -2.36% at ring of the bell on the day assigns it a market valuation of $43.18M. That closing price of SYBX’s stock is at … Synlogic Inc. (NASDAQ:SYBX) Drops -12.93% In One Week: What’s Boosting Its Stock? Read More »
Synlogic Inc. (NASDAQ:SYBX) Drops -12.93% In One Week: What’s Boosting Its Stock? 2022/11/24 16:00:00 Marketing Sentinel
In last trading session, Synlogic Inc. (NASDAQ:SYBX) saw 0.14 million shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $0.62 trading at -$0.02 or -2.36% at ring of the bell on the day assigns it a market valuation of $43.18M. That closing price of SYBX’s stock is at … Synlogic Inc. (NASDAQ:SYBX) Drops -12.93% In One Week: What’s Boosting Its Stock? Read More »
Synlogic GAAP EPS of -$0.25 misses by $0.02, revenue of $0.7M beats by $0.61M 2022/11/10 13:45:13 Seeking Alpha
Synlogic press release (SYBX): Q3 GAAP EPS of -$0.25 misses by $0.02.Revenue of $0.7M (-22.2% Y/Y) beats by $0.61M.
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update 2022/11/10 11:59:00 GlobeNewswire
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023
Synlogic Stock: SYNB1934 Advances To Phase 3 (NASDAQ:SYBX) 2022/10/20 04:30:56 Seeking Alpha
Synlogic''s IP is a genetically altered live bacteria that can be engineered to deliver a specific therapeutic effect. Here''s my take on SYBX''s prospects.
SYBX stock gains after early Phase 2 data for phenylketonuria candidates (NASDAQ:SYBX) 2022/10/18 17:25:37 Seeking Alpha
The clinical-stage biotech Synlogic, Inc. (SYBX) jumped ~10% on Tuesday after the company reported top-line data from the Phase 2 trial for experimental oral drugs SYNB1934 and SYNB1618…
Synlogic appoints Michael Jensen as CFO 2022/03/03 12:36:58 Seeking Alpha
Synlogic (SYBX) has appointed Michael Jensen as CFO. Mr
Synlogic Inc Shares Fall 0.5% Below Previous 52-Week Low - Market Mover 2022/01/14 01:12:46 Kwhen Finance
Synlogic Inc (SYBX) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $142M. The stock is currently down 15.3% year-to-date, down 14.6% over the past 12 months, and down 85.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 37.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2726.8% The company's stock price performance over the past 12 months beats the peer average by -8.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Zacks: Brokerages Expect Synlogic, Inc. (NASDAQ:SYBX) to Announce -$0.28 Earnings Per Share 2021/12/12 18:14:42 Dakota Financial News
Brokerages expect Synlogic, Inc. (NASDAQ:SYBX) to announce earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Synlogics earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.24). Synlogic reported earnings of ($0.39) per share in the same quarter []
Synlogic (NASDAQ:SYBX) Rating Lowered to Hold at Zacks Investment Research 2021/12/10 09:14:42 Dakota Financial News
Synlogic (NASDAQ:SYBX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The companys []